经皮椎间盘摘出联合医用臭氧治疗腰椎间盘突出症

目的探讨经皮髓核摘除术(PLD)联合医用臭氧注射治疗腰椎间盘突出症的临床效果及可行性。方法临床与影像检查确诊为腰椎间盘突出25例,先行PLD,后行椎间盘内及椎旁注射臭氧。结果25例病人治疗后经一年随访,治愈21例,有效24例,无效1例,无一例并发症。结论PLD联合医用臭氧治疗腰椎间盘突出症,安全可靠,可改善治疗效果,减少不良反应,值得推广应用。     

医用臭氧治疗腰椎间盘突出症长期疗效分析

目的 评价经皮椎间盘内臭氧注射治疗腰椎间盘突出症的长期疗效. 方法回顾性分析南方医科大学珠江医院影像中心及南方医院介入治疗科自2002年7月至2004年3月应用臭氧治疗的324例腰椎间盘突出症患者的临床资料.所有患者均随访≥3年,比较术前和最后随访时日本骨科学会(JOA)评分及下肢根性痛的视觉模拟评分(VAS);运用改良的MacNab分级法记录最后随访的临床效果并评价患者年龄、病史长短、突出程度及类型等因素对治疗效果的影响. 结果本组患者JOA评分、下肢根性痛VAS术前及术后终末随访时比较差异均有统计学意义(6.3±1.4 vs 13.1±1.2,P=0.018;7.5±0.8 vs 2.1±0.3,P=0.039),JOA评分、VAS改善率分别为78.2%和70.4%;改良的MacNab分级法记录到最后随访时疗效优良率为77.5%(251/324),患者年龄、病程及椎间盘突出程度对疗效有明显影响;部分(33.8%)包含型突出患者治疗后近期可有症状"反跳".结论 臭氧治疗腰椎间盘突出症术后3年以上随访结果显示疗效令人满意,患者年龄、病程和椎间盘突出程度能影响患者疗效.     

经后、侧后入路臭氧治疗腰椎间盘突出症所致疼痛的对比研究

目的 对比研究经后、侧后入路穿刺臭氧治疗腰椎间盘突出症的镇痛效果.方法 253例满足研究条件的腰椎间盘突出症患者随机分为两组,分别采用后入路(A组,136例)及侧后入路(B组,117例)途径穿刺病变椎间盘并注射医用臭氧.前者注射位置为盘内、突出髓核内及突出部神经根周围,后者注射位置为盘内及椎间孔附近椎旁间隙.术前和术后3个月收集调查问卷和/或通过电话调查完成所需数据采集.主要数据包括下肢根性痛视觉模拟评分(VAS)、Oswestry功能障碍指数(ODI)评分、SF-36量表评分及其手术前后的改变,并做统计学处理.结果 253例患者均按预想成功实施臭氧注射治疗.两组患者除手术部位差异有统计学意义(P＜0.05)外,在年龄、性别比例、病程长短、椎间盘突出程度等方面差异均无统计学意义(P＞0.05).从下肢疼痛VAS评分、ODI评分及SF-36量表评分三方面考察,两组患者均有显著治疗效果(P=0.000),而手术前、后VAS及ODI评分改变,A组明显大于B组(均示P =0.000),SF-36量表评分中躯体疼痛(BP)维度变化A组明显大于B组(P =0.018).治疗优良率A组为90.4％,B组为81.2％,差异有统计学意义(P =0.034),且A组的显效率为41.9％,B组为27.4％.疗效优良的患者疼痛消退至VAS评分5以下的平均时间A组[(15±5)天]小于B组[(19±11)天](P=0.001).结论 相对于侧后入路穿刺途径,后入路穿刺途径治疗腰椎间盘突出症患者镇痛效果较高,疼痛减轻程度较大,疼痛消退速度较快,可根据实际情况选用.     

经皮臭氧靶点注射治疗重度腰椎间盘突出症疗效分析

目的评估CT介导下后入路经椎管及硬膜囊椎间盘内医用臭氧注射治疗重度腰椎间盘突出症的疗效及优势。方法 36例重度腰椎间盘突出症患者于CT介导下从背部棘突旁开约1～2 cm后入路经椎管及硬膜囊穿刺到达椎间盘内,臭氧注射于椎间盘、突出髓核及患侧硬膜外间隙神经根周围。椎间盘及突出髓核内医用臭氧浓度为40～50μg/ml,神经根旁医用臭氧浓度为30μg/ml。结果 36例患者均治疗成功。术前平均下肢根性痛视觉模拟评分(VAS)为(8.34±1.62)分,Oswestry功能障碍指数(ODI)评分平均为(61.75±12.44)分;术后6个月随访VAS评分平均为(3.97±0.53)分,ODI评分平均为(38.28±7.76)分;术前及术后VAS及ODI评分差异均有统计学意义(P值均<0.001)。按照ODI评分区段分布,5例达到优,21例达到良,7例可,3例差,总优良率达72.2%。15例共注射臭氧2次,13例(86.7%)取得优良疗效。全部患者均未见严重并发症。结论 CT介导下后入路经椎管及硬膜囊腰椎间盘内医用臭氧注射治疗重度腰椎间盘突出症安全、注射准确、疗效好,可作为备选方法,根据实际情况选择应用。     

医用臭氧治疗腰椎间盘突出症长期疗效分析

Objective To evaluate the leng-term effect ofpercutaneous ozone injection into the intervertebral space for treatment of lumbar disc herniation. Methods A retrospective analysis of the clinical data was performed in 324 patients with lumbar disc herniation admitted in Zhujiang Hospital and Nanfang Hospital, Southern Medical University between April, 2000 and March, 2004. All the patients were treated with percutaneous ozone injection into the intervertebral space and followed up for no less than 3 years. The scores of the Japanese Orthopedics Association (JOA) and sciatica Visual Analog Scales (VAS) before and at the end of the follow-up were recorded and compared. The modified MacNab criteria were adopted for evaluation of the effect of the treatment. The patients' age, disease course, severity of disc herniation and type of herniation were also analyzed in relation to the therapeutic effect. Results Compared with the scores recorded before the operation, the average scores of JOA and VAS increased significantly at the end of the follow-up (6.3±1.4 vs 13.1±1.2 for JOA, P=0.0178;7.5±0.8 vs 2.1±0.3 for VAS, P=0.039), with JOA and VAS improvement rates of 78.2% and 70.4%, respectively. According to modified MacNab criteria, good therapeutic effect was achieved in 77.5% (251/234) of the cases, the patients' age, the disease course and severity of disc herniation showed significant impact on the therapeutic effect. More than one third of the patients (33.8%) with herniation of inclusion type experienced symptom relapse early after the treatment. Conclusion The 3-year follow-up data show that ozone treatment produces satisfactory long-term effect on lumbar disc herniation. The patient's age, disease course and severity of herniation are three important factors that affect the long-term therapeutic effect.     

后入路经椎管及硬膜囊臭氧靶点注射治疗腰椎间盘突出症

摘要：目的评估CT介导下后入路经椎管及硬膜囊椎间盘内医用臭氧精确注射治疗腰椎间盘突出症的疗效及优势。方法262
例腰椎间盘突出症患者于CT介导下从背部棘突旁开约1~2 cm后入路经椎管及硬膜囊穿刺到达椎间盘内,臭氧注射靶点为
椎间盘、突出髓核及患侧硬膜外间隙神经根周围。椎间盘及突出髓核内医用臭氧浓度40~50 μg/ml,神经根旁医用臭氧浓度
30 μg/ml。结果所有患者治疗成功。术前平均JOA评分为（8.30±1.40）分,下肢根性痛VAS评分平均为（8.73±0.80）分;术后3
月随访JOA评分平均为（24.16±3.20）分,下肢根性痛VAS评分平均为（2.41±0.20）分;术前及术后JOA评分和VAS评分均存在
显著差异（P值分别0.0158和0.0242）。按照改良的MacNab分级法,165例患者达到优,64例达到良,可20例,差13例,总优良率
达87.4%。全部患者均未见任何严重并发症。结论CT介导下后入路经椎管及硬膜囊腰椎间盘内医用臭氧注射能够达到精确
的靶点注射,手术安全,可以提高治疗腰椎间盘突出症的效果。